Clinical Observation of Intensive Rosuvastatin Therapy in the Treatment of Acute Coronary Syndrome
10.6039/j.issn.1001-0408.2017.11.20
- VernacularTitle:急性冠脉综合征患者接受强化剂量瑞舒伐他汀治疗的临床观察
- Author:
Mei LIU
;
Guiwei LI
- Keywords:
Acute coronary syndrome;
Rosuvastatin;
Major adverse cardiac event;
Blood lipid;
Prognosis
- From:
China Pharmacy
2017;28(11):1510-1513
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe long-term efficacy of intensive rosuvastatin therapy in the treatment of acute coronary syn-drome (ACS) and explore its possible mechanism,so as to provide reference for clinical diagnosis and treatment. METHODS:ACS patients receiving rosuvastatin after cured in our hospital during Jan. 2013-Jan. 2015 were divided into observation group(55 cases)and control group(47 cases)according to the dose of rosuvastatin. Under same guidance of physicans,2 groups were addi-tionally given Rosuvastatin calcium tablets(20 mg for observation group,10 mg for control group,qd,po)orally on the basis of routine treatment. Both groups were treated for 1 year. The incidence of 1-year accumulative main adverse cardiac event (MACE) were compared between 2 groups as well as the levels of blood lipid and serum cytokines,the occurrence of ADR before treat-ment,after 3 months of treatment. RESULTS:The incidence of accumulative MACE in observation group was significantly lower than control group,with statistical significance (P<0.05). After treatment,the levels of TC and LDL-C in 2 groups were de-creased significantly;the level of LDL-C was inCreased significantly compared to before treatment,and the observation group was significantly lower than the control group,with statistical significance(P<0.05). The levels of IL-1β and TNF-α in 2 groups were decreased significantly (P<0.05);the observation group was significantly lower than the control group,with statistical signifi-cance (P<0.05). The peripheral blood LDL-C was positively correlated with IL-1β and TNF-α in observation group after treat-ment,with statistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Intensive rosuvastatin therapy can significantly improve the long-term prognosis for ACS patients,which may associate with lipid metabolic regulation and anti-inflammatory effect.
